410 related articles for article (PubMed ID: 26970716)
1. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
Young G; Collins PW; Colberg T; Chuansumrit A; Hanabusa H; Lentz SR; Mahlangu J; Mauser-Bunschoten EP; Négrier C; Oldenburg J; Patiroglu T; Santagostino E; Tehranchi R; Zak M; Karim FA
Thromb Res; 2016 May; 141():69-76. PubMed ID: 26970716
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
[TBL] [Abstract][Full Text] [Related]
3. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
Negrier C; Young G; Abdul Karim F; Collins PW; Hanabusa H; Colberg T; Goldman B; Walsh CE;
Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
[TBL] [Abstract][Full Text] [Related]
4. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
Escobar MA; Tehranchi R; Karim FA; Caliskan U; Chowdary P; Colberg T; Giangrande P; Giermasz A; Mancuso ME; Serban M; Tsay W; Mahlangu JN
Haemophilia; 2017 Jan; 23(1):67-76. PubMed ID: 27480487
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
[TBL] [Abstract][Full Text] [Related]
6. Nonacog Beta Pegol: A Review in Haemophilia B.
Syed YY
Drugs; 2017 Dec; 77(18):2003-2012. PubMed ID: 29124682
[TBL] [Abstract][Full Text] [Related]
7. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
[TBL] [Abstract][Full Text] [Related]
8. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
[TBL] [Abstract][Full Text] [Related]
10. GlycoPEGylated recombinant factor IX for hemophilia B in context.
Santagostino E; Mancuso ME
Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
12. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Collins PW; Young G; Knobe K; Karim FA; Angchaisuksiri P; Banner C; Gürsel T; Mahlangu J; Matsushita T; Mauser-Bunschoten EP; Oldenburg J; Walsh CE; Negrier C;
Blood; 2014 Dec; 124(26):3880-6. PubMed ID: 25261199
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
[TBL] [Abstract][Full Text] [Related]
14. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
Ezban M; Hermit MB; Persson E
Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
[TBL] [Abstract][Full Text] [Related]
15. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
Chan AK; Alamelu J; Barnes C; Chuansumrit A; Garly ML; Meldgaard RM; Young G
Res Pract Thromb Haemost; 2020 Oct; 4(7):1101-1113. PubMed ID: 33134776
[TBL] [Abstract][Full Text] [Related]
16. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
Martinowitz U; Lissitchkov T; Lubetsky A; Jotov G; Barazani-Brutman T; Voigt C; Jacobs I; Wuerfel T; Santagostino E
Haemophilia; 2015 Nov; 21(6):784-90. PubMed ID: 25990590
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
[TBL] [Abstract][Full Text] [Related]
18. Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.
Fukutake K; Taki M; Matsushita T; Sakai M; Takata A; Yamaguchi H; Karumori T
Haemophilia; 2019 Jul; 25(4):e247-e256. PubMed ID: 31168882
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]